Epoetin alfa: basic biology and clinical utility in cancer patients

References

• Law ML, Cai GY, Lin FK et al. Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism. Proc. Natl Acad. Sci. USA 83, 6920–6924 (1986).
   PubMed Web of Science ®Google Scholar
• Lacombe C, Mayeux P. Biology of erythropoietin. Haematologica 83, 724–732 (1998).
   PubMed Web of Science ®Google Scholar
• Kendall RG. Erythropoietin. Clin. Lab. Haematol. 23, 71–80 (2001).
   PubMedGoogle Scholar
• Inoue N, Takeuchi M, Ohashi H, Suzuki T. The production of recombinant human erythropoietin. Biotechnol. Ann. Rev. 1, 297–313 (1995).
   PubMedGoogle Scholar
• Romanowski RR, Sytkowski AJ. The molecular structure of human erythropoietin. Hematol. Oncol. Clin. North Am. 8, 885–894 (1994).
   PubMedGoogle Scholar
• Storring PL, Tiplady RJ, Gaines Das RE et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br. J. Haematol. 100, 79–89 (1998).
   PubMed Web of Science ®Google Scholar
• Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283, 990–993 (1999).
   PubMed Web of Science ®Google Scholar
• Cheung JY, Miller BA. Molecular mechanisms of erythropoietin signaling. Nephron 87, 215–222 (2001).
   PubMedGoogle Scholar
• Silva M, Benito A, Sanz C et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J. Biol. Chem. 274, 22165–22169 (1999).
   PubMed Web of Science ®Google Scholar
• Parganas E, Wang D, Stravopodis D et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385–395 (1998).
   PubMed Web of Science ®Google Scholar
• Socolovsky M, Nam H, Fleming MD et al. Ineffective erythropoiesis in Stat5a (-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 98, 3261–3273 (2001).
   PubMed Web of Science ®Google Scholar
• Dolznig H, Habermann B, Stangl K et al. Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts. Curr. Biol. 12, 1076–1085 (2002).
   PubMed Web of Science ®Google Scholar
• Kralovics R, Indrak K, Stopka T et al. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 90, 2057–2061 (1997).
   PubMed Web of Science ®Google Scholar
• Wickrema A, Krantz SB, Winkelmann JC, Bondurant MC. Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood 80, 1940–1949 (1992).
   PubMed Web of Science ®Google Scholar
• Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9(Suppl. 5), 18–30 (2004).
   PubMed Web of Science ®Google Scholar
• Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury. Proc. Natl Acad. Sci. USA 97, 10526–10531 (2000).
   PubMed Web of Science ®Google Scholar
• Selzer E, Wacheck V, Kodym R et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res. 10, 421–426 (2000).
   PubMedGoogle Scholar
• Rosti V, Pedrazzoli P, Ponchio L et al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 78, 208–212 (1993).
   PubMedGoogle Scholar
• Westphal G, Niederberger E, Blum C et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori. 88, 150–159 (2002).
   PubMedGoogle Scholar
• Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 58, 647–657 (2000).
   PubMed Web of Science ®Google Scholar
• Arcasoy MO, Amin K, Karayal AF et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab. Invest. 82, 911–918 (2002).
   PubMed Web of Science ®Google Scholar
• Busse L, Sinclair A, Rogers N et al. Is EPO receptor overexpressed in human tomor cells? Proc. Am. Assoc. Cancer Res. 46, 1077 (2005).
   Google Scholar
• Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 322, 1693–1699 (1990).
   PubMed Web of Science ®Google Scholar
• Abels R. Erythropoietin for anaemia in cancer patients. Eur. J. Cancer 29A(Suppl. 2), S2–S8 (1993).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 86, 4446–4453 (1995).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Boogaerts MA, Cimino R et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma-a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Blood 87, 2675–2682 (1996).
   PubMed Web of Science ®Google Scholar
• Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br. J. Haematol. 113, 172–179 (2001).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Brandberg Y, Molostova V et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J. Clin. Oncol. 20, 2486–2494 (2002).
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19, 2865–2874 (2001).
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol. 19, 2875–2882 (2001).
   PubMed Web of Science ®Google Scholar
• Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J. Clin. Oncol. 15, 1218–1234 (1997).
   PubMed Web of Science ®Google Scholar
• Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J. Clin. Oncol. 16, 3412–3425 (1998).
   PubMed Web of Science ®Google Scholar
• Reinhardt U, Tulusan A, Angermund R, Lutz H. Increased hemoglobin levels and improved quality-of-life assessments during epoetin alfa treatment in anemic cancer patients: results of a prospective, multicenter German trial. Oncologist 10, 225–237 (2005).
   PubMed Web of Science ®Google Scholar
• Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J. Clin. Oncol. 23, 2597–2605 (2005).
   PubMed Web of Science ®Google Scholar
• Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int. Suppl. 69, S61–S66 (1999).
   PubMed Web of Science ®Google Scholar
• Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 22, 1301–1307 (2004).
   PubMed Web of Science ®Google Scholar
• Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am. J. Hematol. 76, 74–78 (2004).
   Google Scholar
• Stasi R, Amadori S, Littlewood TJ et al. Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns. Oncologist 10, 539–554 (2005).
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Zagari M, Pallister C, Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 8, 99–107 (2003).
   PubMed Web of Science ®Google Scholar
• Fallowfield L, Gagnon D, Zagari M et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br. J. Cancer 87, 1341–1353 (2002).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91, 2214–2221 (2001).
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362, 1255–1260 (2003).
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 23, 5960–5972 (2005).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Brandberg Y, Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow-up of a large randomized study. Br. J. Haematol. 129, 206–209 (2005).
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br. J. Haematol. 89, 67–71 (1995).
   PubMed Web of Science ®Google Scholar
• Terpos E, Mougiou A, Kouraklis A et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a Phase II trial in 281 patients. Br. J. Haematol. 118, 174–180 (2002).
   PubMed Web of Science ®Google Scholar
• Spiriti MA, Latagliata R, Niscola P et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann. Hematol. 84, 167–176 (2005).
   PubMed Web of Science ®Google Scholar
• Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 106, 803–811 (2005).
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E, Negrin R, Stein R et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br. J. Haematol. 99, 344–351 (1997).
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br. J. Haematol. 120, 1037–1046 (2003).
   PubMed Web of Science ®Google Scholar
• Rizzo J, Lichtin AE, Woolf SH et al. Use of Epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J. Clin. Oncol. 20, 4083–4107 (2002).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur. J. Cancer 40, 2201–2216 (2004).
   PubMed Web of Science ®Google Scholar
• Peces R, de la Torre M, Alcazar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N. Engl. J. Med. 335, 523–524 (1996).
   PubMed Web of Science ®Google Scholar
• Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin. Nephrol. 47, 331–335 (1997).
   PubMed Web of Science ®Google Scholar
• Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 469–475 (2002).
   PubMed Web of Science ®Google Scholar
• Bennett CL, Luminari S, Nissenson AR et al. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. 351, 1403–1408 (2004).
   PubMed Web of Science ®Google Scholar
• Locatelli F, Aljama P, Barany P et al. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? Nephrol. Dial. Transplant 19, 288–293 (2004).
   PubMedGoogle Scholar
• Quint L, Casadevall N, Giraudier S. Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins. Br. J. Haematol. 124, 842 (2004).
   PubMed Web of Science ®Google Scholar
• Bohlius J, Langensiepen S, Schwarzer G et al. Erythropoietin for patients with malignant disease. Cochrane Database Syst. Rev. CD003407 (2004).
   Google Scholar
• Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br. J. Cancer 78, 781–787 (1998).
   PubMed Web of Science ®Google Scholar
• Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 40, 2293–2306 (2004).
   PubMed Web of Science ®Google Scholar
• Pealer LN, Marfin AA, Petersen LR et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N. Engl. J. Med. 349, 1236–1245 (2003).
   PubMed Web of Science ®Google Scholar